title: Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.
abstract: Raloxifene is a second-generation selective estrogen receptor modulator used for the prevention and treatment of osteoporosis and the prevention of breast cancer in postmenopausal women. Raloxifene is extensively metabolized by glucuronidation to form raloxifene-6-glucuronide (ral-6-Gluc) and raloxifene-4'-glucuronide (ral-4'-Gluc). The goal of the present study was to determine whether functional polymorphisms in active UGTs could play a role in altered raloxifene glucuronidation in vivo. Using homogenates from HEK293 UGT-overexpressing cell lines, raloxifene was shown to be glucuronidated primarily by the hepatic UGTs 1A1 and 1A9 and the extra-hepatic UGTs 1A8 and 1A10; no detectable raloxifene glucuronidation activity was found for UGT2B enzymes. Functional UGT1A1 transcriptional promoter genotypes were significantly (Ptrend = 0.005) associated with ral-6-Gluc formation in human liver microsomes, and, consistent with the decreased raloxifene glucuronidation activities observed in vitro with cell lines overexpressing UGT1A8 variants, the UGT1A8*2 variant was significantly (P = 0.023) correlated with total raloxifene glucuronide formation in human jejunum homogenates. While ral-4'-Gluc exhibited 1:100th the anti-estrogenic activity of raloxifene itself as measured by binding to the estrogen receptor, raloxifene glucuronides comprised about 99% of the circulating raloxifene dose in raloxifene-treated subjects, with ral-4'-Gluc comprising ~70% of raloxifene glucuronides. Plasma ral-6-Gluc (Ptrend = 0.0025), ral-4'-Gluc (Ptrend = 0.001), and total raloxifene glucuronides (Ptrend = 0.001) were increased in raloxifene-treated subjects who were predicted slow metabolizers [UGT1A8 (*1/*3)] versus intermediate metabolizers [UGT1A8 (*1/*1) or UGT1A8 (*1/*2)] versus fast metabolizers [UGT1A8 (*2/*2). These data suggest that raloxifene metabolism may be dependent on UGT1A8 genotype and that UGT1A8 genotype may play an important role in overall response to raloxifene.
authors.affiliation: Department of Pharmacology, Pennsylvania State College of Medicine, Hershey, Pennsylvania, USA.
authors.forename: Dongxiao
authors.initials: D
authors.lastname: Sun
authors.forename: Nathan R
authors.initials: NR
authors.lastname: Jones
authors.forename: Andrea
authors.initials: A
authors.lastname: Manni
authors.forename: Philip
authors.initials: P
authors.lastname: Lazarus
mesh_terms: D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D002478:Cells, Cultured; D004965:Estrogen Antagonists / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005838:Genotype; D020719:Glucuronides / Q000097:blood*; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D007583:Jejunum / Q000378:metabolism; D008862:Microsomes, Liver / Q000378:metabolism; D011110:Polymorphism, Genetic / Q000235:genetics; D020849:Raloxifene Hydrochloride / Q000378:metabolism* / Q000627:therapeutic use*; D053719:Tandem Mass Spectrometry
chemical_list: D004965:Estrogen Antagonists; D020719:Glucuronides; D020849:Raloxifene Hydrochloride; D014453:Glucuronosyltransferase; C454320:UDP-glucuronosyltransferase, UGT1A8